新凤鸣：拟1亿元增资合肥利夫生物科技公司

Core Viewpoint - The company plans to invest 100 million yuan in Hefei Lif Biotechnology Co., Ltd., acquiring a 7.0175% stake in the company [1] Group 1 - The investment does not constitute a related party transaction and is not classified as a major asset restructuring [1] - The investment risks include uncertainties in market demand, post-investment management risks, and uncertainties in expected investment returns [1]